24 May 2013
Keywords: myogen, ambrisentan, sees, good, ph, ii, data
Article | 22 August 2005
Myogen, a US biopharmaceutical company focused on small-molecule therapeutics for cardiovascular disorders, says that positive results
from a Phase II ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 August 2005
23 May 2013
© 2013 thepharmaletter.com